INFERR-Iron infusion in haemodialysis study: INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis—a protocol for a prospective open-label blinded endpoint randomised controlled trial

INFERR-Iron infusion in haemodialysis study: INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis—a protocol for a prospective open-label blinded endpoint randomised controlled trial

Abstract Background The effectiveness of erythropoiesis-stimulating agents, which are the main stay of managing anaemia of chronic kidney disease (CKD), is largely dependent on adequate body iron stores. The iron stores are determined by the levels of serum ferritin concentration and transferrin sat...

Full description

Bibliographic Details
Main Authors: Sandawana William Majoni, Jane Nelson, Darren Germaine, Libby Hoppo, Stephanie Long, Shilpa Divakaran, Brandon Turner, Jessica Graham, Sajiv Cherian, Basant Pawar, Geetha Rathnayake, Bianca Heron, Louise Maple-Brown, Robert Batey, Peter Morris, Jane Davies, David ( Kiran) Fernandes, Madhivanan Sundaram, Asanga Abeyaratne, Yun Hui Sheryl Wong, Paul D. Lawton, Sean Taylor, Federica Barzi, Alan Cass, for the INFERR study Group
Format: Article
Language:English
Published: BMC 2021-12-01
Series:Trials
Subjects:
Aboriginal and Torres Strait Islander Australians
First Nations Australians
Anaemia
Chronic kidney disease
Maintenance haemodialysis
Ferritin
Online Access:https://doi.org/10.1186/s13063-021-05854-w

Internet

https://doi.org/10.1186/s13063-021-05854-w

Similar Items